Feat: Suicide Risk in Men's Cancers

The Psychological Burden of Diagnosis

Written by: Lennard M. Goetze, Ed.D  / Barbara Bartlik, MD

A diagnosis of male breast cancer is not only a medical event—it is a deeply personal and often isolating psychological rupture. For many men, the diagnosis carries a dual burden: confronting a life-threatening disease while navigating a condition widely perceived as “female.” In a single moment, patients are forced to reconcile mortality, uncertainty, and a profound shift in identity. Despite advances in detection and treatment, the emotional toll of diagnosis in men remains underrecognized and insufficiently addressed. Among the most serious consequences is an elevated risk of depression, anxiety, and, in some cases, suicide—particularly in the early stages following diagnosis.

Research indicates that individuals diagnosed with cancer face a significantly higher risk of suicide compared to the general population, and men represent the majority of these cases. In male breast cancer, this vulnerability may be intensified by stigma, lack of awareness, and limited peer support networks. The period of greatest risk occurs within the first six months to one year following diagnosis—a time marked by psychological shock, disorientation, and fear of the unknown.

The moment of diagnosis often triggers a cascade of emotional responses: disbelief, confusion, anger, and profound distress. For men, this experience can be further complicated by feelings of embarrassment or reluctance to openly discuss the condition. Many are suddenly required to process complex medical information while confronting concerns about masculinity, body image, sexuality, financial stability, and survival. Treatment-related changes—such as surgery or hormonal therapy—may further challenge self-perception and emotional resilience.

Compounding this burden is the tendency among men to delay seeking emotional support. In the absence of early intervention, intrusive thoughts, anxiety, and hopelessness can take hold, particularly when patients feel alone in their experience. Without adequate guidance, reassurance, and connection to others who have faced similar diagnoses, the psychological impact can deepen during this critical early phase.

Recognizing and addressing these unique challenges is essential. Male breast cancer patients require not only expert clinical care, but also immediate, structured psychological support, clear communication at the time of diagnosis, and access to peer communities that normalize their experience. Early intervention can transform a moment of crisis into a pathway toward resilience, understanding, and long-term survivorship.

Men at Risk: The Overlooked Suicide Crisis in Serious Illness Suicide remains a critical yet underrecognized public health crisis among men—one that becomes even more urgent in the context of cancer and other debilitating diseases. Epidemiologic data consistently show that men account for nearly 80% of all suicide deaths in the United States, with rates approximately four times higher than women. This disparity widens with age, as men over 75 exhibit the highest suicide rates of any demographic group—an alarming overlap with populations most affected by cancer. Within oncology, the risk intensifies further. Male cancer patients represent the vast majority of suicide cases in this population, with studies indicating they account for more than 80% of cancer-related suicides. The convergence of factors—including poor prognosis, physical symptom burden, and psychological distress—creates a high-risk environment, particularly in the first year following diagnosis. Compounding this vulnerability is a well-documented reluctance among men to seek mental health support, along with higher rates of undiagnosed depression and social isolation. These findings underscore a critical gap in care. Suicide in men—especially those facing serious illness—is not simply a mental health issue, but a multidimensional clinical challenge requiring early identification, integrated psychosocial support, and sustained intervention throughout the continuum of care.

PART 2: STATISTICAL ANALYSIS IN THE CANCER SPHERE

Demographic patterns further illuminate vulnerability. Suicide rates among cancer patients are disproportionately higher in older white males, particularly those over the age of 50. This may reflect a convergence of factors, including social isolation, reduced likelihood of seeking psychological support, cultural expectations surrounding masculinity, and the perceived loss of autonomy or purpose following illness. Additionally, patients with cancers associated with poor prognoses—such as lung, pancreatic, and head and neck cancers—demonstrate higher rates of suicide. These diagnoses often carry not only a shortened life expectancy but also significant symptom burdens, including pain, disfigurement, or functional impairment.

Figure 1 (L). Relative Suicide Risk Following Cancer Diagnosis (Conceptual Model Based on Epidemiologic Trends) - This figure illustrates the elevated risk of suicide among cancer patients, which peaks at the time of diagnosis and remains highest during the first 6–12 months. Risk gradually declines over time but continues to exceed that of the general population for several years. The trend reflects the combined impact of psychological shock, symptom burden, and prognosis-related distress, emphasizing the importance of early intervention and sustained psychosocial support.

Importantly, it is not the diagnosis alone that drives suicide risk, but the lived experience of the disease. High symptom burden—chronic pain, fatigue, neurological impairment, or treatment toxicity—can erode quality of life to the point where patients feel trapped in an intolerable state. When combined with depression, which is highly prevalent in oncology populations, the risk escalates further. Some studies suggest that a substantial proportion of patients who die by suicide had either a newly diagnosed or previously unrecognized cancer, underscoring the psychological shock as a critical trigger.

Surgical intervention and treatment milestones also represent periods of heightened vulnerability. Data suggests that a small but notable percentage of suicides occur within the first month following major surgery, when patients may be coping with physical trauma, altered body image, and uncertainty about outcomes. Over a longer timeline, approximately half of suicides in cancer patients occur within the first three years after diagnosis, reflecting the sustained psychological burden of living with illness.

While encouraging trends indicate that suicide rates among cancer patients may be gradually declining, they remain consistently higher than those observed in the general population. Large-scale analyses of cancer survivors reveal that although the overall percentage of suicide deaths is relatively small, the impact is profound and preventable. Each case represents not only a loss of life but also a failure to adequately address the emotional and psychological dimensions of care.

Figure 2(L). Relative Suicide Risk by Cancer Type (Conceptual Model Based on Epidemiologic Trends) This chart highlights variation in suicide risk across cancer types, with lung, head and neck, and pancreatic cancers demonstrating the highest relative risk compared to the general population. These patterns are closely associated with poorer prognoses, higher symptom burden, and greater functional or psychological distress. The data underscores the importance of targeted psychosocial screening and intervention in high-risk oncology populations.

The implications for clinical practice are clear. Early psychological intervention must be considered an essential component of cancer care, not an optional adjunct. Screening for depression, anxiety, and suicidal ideation should begin at diagnosis and continue throughout the treatment continuum. Multidisciplinary approaches—including mental health professionals, social workers, rehabilitation specialists, and patient navigators—are critical in addressing the complex needs of this population.

Equally important is the role of communication. How a diagnosis is delivered can significantly influence a patient’s psychological trajectory. Compassionate, clear, and supportive communication can mitigate the initial shock and help patients feel less isolated in their experience. Providing realistic hope—grounded in treatment options, symptom management, and quality-of-life interventions—can counterbalance feelings of despair.

Programs focused on survivorship and rehabilitation, such as integrative care models, also play a vital role in restoring a sense of agency. By addressing pain, functional limitations, and overall well-being, these approaches help patients regain control over their bodies and their lives. This shift—from passive recipient of care to active participant in recovery—can be a powerful antidote to hopelessness.

Ultimately, suicide in the context of cancer and debilitating illness is not solely a psychiatric issue; it is a systemic challenge that reflects gaps in how healthcare addresses suffering. As survival rates improve, the focus must expand beyond extending life to preserving its quality and meaning. Recognizing and addressing the psychological impact of diagnosis is not only compassionate care—it is lifesaving care.

 

 

References

* Centers for Disease Control and Prevention. (2024). Suicide data and statistics.
https://www.cdc.gov/suicide/facts/data.html

* National Institute of Mental Health. (2024). Suicide statistics.
https://www.nimh.nih.gov/health/statistics/suicide

* American Foundation for Suicide Prevention. (2024). Suicide statistics.
https://afsp.org/suicide-statistics

* Centers for Disease Control and Prevention
Garnett, M. F., et al. (2024). Suicide mortality in the United States, 2002–2022. National Center for Health Statistics Data Brief.
https://www.cdc.gov/nchs/products/databriefs/db509.htm

* Kaiser Family Foundation. (2026). Suicide deaths: National trends and variation by demographics.
https://www.kff.org/mental-health/suicide-deaths-national-trends-and-variation-by-demographics-and-states/

* Psychiatric Times. (2026). Men’s mental health: Redefining strength in a changing world.
https://www.psychiatrictimes.com

* UCLA Health. (2022). Most male suicides show no prior mental health diagnosis.
https://newsroom.ucla.edu

* American Cancer Society. (2023). Cancer facts & figures 2023. American Cancer Society. https://www.cancer.org

* National Cancer Institute. (2022). Depression (PDQ®)–Health professional version. U.S. Department of Health and Human Services. https://www.cancer.gov

* JAMA Psychiatry-  Misono, S., Weiss, N. S., Fann, J. R., Redman, M., & Yueh, B. (2008). Incidence of suicide in persons with cancer. JAMA Psychiatry, 65(6), 653–661. https://doi.org/10.1001/archpsyc.65.6.653

* Journal of Clinical Oncology- Anguiano, L., Mayer, D. K., Piven, M. L., & Rosenstein, D. (2012). A literature review of suicide in cancer patients. Journal of Clinical Oncology, 30(5), 530–538. https://doi.org/10.1200/JCO.2011.36.1580

*  CA: A Cancer Journal for Clinicians - Rahouma, M., Kamel, M., Abouarab, A., et al. (2017). Lung cancer patients have the highest malignancy-associated suicide rate in the United States. CA: A Cancer Journal for Clinicians, 67(6), 435–444. https://doi.org/10.3322/caac.21401

* BMJ- Fang, F., Fall, K., Mittleman, M. A., et al. (2012). Suicide and cardiovascular death after a cancer diagnosis. BMJ, 344, e268. https://doi.org/10.1136/bmj.e268

 

 

Cancer Therapies and Osteoporosis (UNOFFICIAL- NOT FOR DISTRIBUTION)

 

THE HIDDEN COST OF SURVIVAL:

How Cancer Therapies Accelerate Bone Loss in Men

By: Lennard M. Goetze, Ed.D

 

Cancer treatment has made extraordinary strides—extending life, improving outcomes, and transforming once-fatal diagnoses into manageable conditions. Yet beneath these successes lies a quieter, often overlooked consequence: the progressive weakening of the skeletal system. For many male cancer patients, especially those undergoing aggressive or long-term therapies, the risk of osteoporosis is not incidental—it is biologically driven, predictable, and, in many cases, preventable with early awareness.

 

A Silent Shift in Bone Biology

Healthy bone is not static. It is a dynamic tissue constantly undergoing remodeling—a balance between bone formation (by osteoblasts) and bone resorption (by osteoclasts). Cancer therapies disrupt this balance. When the body is exposed to certain drugs or hormone-altering treatments, bone breakdown begins to outpace repair, leading to reduced density, compromised structure, and ultimately, fragility.

 

In men, this process is often intensified by hormonal disruption. Testosterone plays a crucial role in maintaining bone strength. When cancer treatments interfere with hormone production or signaling, the skeletal system becomes one of the earliest and most significantly affected targets.

 

 

Androgen Deprivation Therapy: A Double-Edged Sword

Among the most well-documented contributors to bone loss in men is androgen deprivation therapy (ADT), commonly used in the treatment of prostate cancer. By design, ADT suppresses testosterone to slow tumor growth. However, this same mechanism accelerates skeletal deterioration.

 

Without adequate testosterone, the normal cycle of bone renewal becomes unbalanced. Bone resorption increases, while formation declines. Over time, this leads to measurable declines in bone mineral density (BMD), often within the first year of therapy. Longitudinal observations have shown that men on prolonged ADT can face a dramatic escalation in osteoporosis risk, along with a corresponding rise in fracture incidence.

 

This creates a paradox: while ADT may control cancer progression, it simultaneously compromises the structural integrity that supports mobility, independence, and overall quality of life.

 

Chemotherapy and Direct Bone Toxicity

Beyond hormonal therapies, several chemotherapeutic agents exert direct toxic effects on bone tissue. Drugs such as methotrexate and ifosfamide interfere with cellular replication—not only in cancer cells but also in the bone-forming osteoblasts. This suppression reduces the body’s ability to rebuild and maintain bone mass.

 

In addition, chemotherapy can alter the bone marrow environment, where critical signaling pathways for bone regeneration originate. The result is a compounded effect: decreased bone formation, increased vulnerability to microdamage, and impaired recovery from routine stress.

Another pathway involves treatment-induced hypogonadism. Certain chemotherapies can damage the testes, reducing testosterone production even after treatment has ended. This secondary hormonal deficiency can persist long-term, placing survivors at continued risk for accelerated bone loss well into survivorship.

 

The Role of Supportive Medications

Glucocorticoids—commonly prescribed alongside chemotherapy to manage inflammation, nausea, or immune-related complications—represent another significant threat to bone health. These medications impair calcium absorption, suppress osteoblast function, and increase bone resorption.

 

Over time, chronic exposure to steroids can produce rapid and substantial declines in bone density. This effect is particularly concerning when layered on top of other treatment-related risks, creating a cumulative burden on skeletal integrity.

 

Quantifying the Risk: Bone Loss and Fractures

Clinical observations consistently show that men undergoing cancer treatment may experience accelerated declines in bone mineral density—sometimes at rates far exceeding those seen in age-related osteoporosis. The hip and lumbar spine, both critical weight-bearing regions, are especially vulnerable.

 

This loss is not merely a laboratory finding. It translates into real-world consequences: increased susceptibility to fractures, prolonged recovery times, and, in many cases, permanent reductions in mobility. For older patients, a single fracture—particularly of the hip—can mark a turning point toward loss of independence and overall health decline.

 

Importantly, these risks are not confined to active treatment periods. Many cancer survivors continue to face elevated fracture risk years after therapy has concluded, underscoring the need for long-term monitoring.

 

 

Early Detection: A Missed Opportunity

Despite the clear association between cancer therapies and bone loss, screening is often underutilized. Tools such as DEXA scan (dual-energy X-ray absorptiometry) provide a noninvasive and highly accurate method for assessing bone mineral density. Yet many patients do not receive baseline or follow-up evaluations.

Emerging imaging approaches—including advanced ultrasound techniques and metabolic bone markers—are beginning to offer additional insight into bone quality and turnover. These modalities may play an increasingly important role in identifying early changes before significant loss occurs.

 

The principle is simple: what is not measured cannot be managed. Incorporating routine bone health assessments into cancer care protocols represents a critical step toward prevention.

 

Prevention and Intervention: Rebuilding Strength from Within

The good news is that treatment-related bone loss is not inevitable. With proactive management, patients can significantly reduce their risk of osteoporosis and fractures.

 

Lifestyle strategies form the foundation of prevention. Weight-bearing and resistance exercises stimulate bone formation and improve muscular support, reducing fall risk. Nutritional optimization—including adequate intake of calcium and vitamin D—supports skeletal health at a biochemical level.

Pharmacologic interventions also play a role. Medications such as bisphosphonates and other bone-modifying agents can help slow resorption and preserve bone density in high-risk patients. When used appropriately, these therapies can stabilize or even improve bone metrics over time.

 

Equally important is addressing hormonal balance. In select cases, careful evaluation of testosterone levels and endocrine function may guide additional supportive strategies.

 

A Call for Integrated Care

The link between cancer treatment and osteoporosis highlights a broader issue in modern medicine: the need for integrated, whole-patient care. Survival is no longer the sole endpoint. Quality of life, functional independence, and long-term resilience must be part of the equation.

 

For clinicians, this means recognizing bone health as a core component of oncology care—not an afterthought. For patients, it means understanding that vigilance does not end when treatment concludes.

The skeleton tells a story—of strength, adaptation, and vulnerability. In the context of cancer therapy, it also tells a warning: that life-saving treatments can carry hidden costs. The challenge, and the opportunity, lies in addressing these risks early, intelligently, and comprehensively.

 

Because preserving life should never come at the expense of the very structure that supports it.

 

 Part 2

EARLY DETECTION OF OSTEOPOROSIS:

Seeing the Risk Before the Fracture

By Dr. Robert L. Bard, MD, DABR, FAIUM, FASLMS

Osteoporosis is often discovered too late—after a fracture, when the structural integrity of bone has already been compromised. In my clinical experience, the true opportunity lies not in reacting to fractures, but in identifying vulnerability years before they occur. Early detection transforms osteoporosis from a crisis into a manageable condition. The challenge is that bone loss is silent. Patients feel strong, active, and asymptomatic while microarchitectural deterioration quietly progresses beneath the surface. This is where imaging becomes essential—not just as a diagnostic tool, but as a predictive instrument.

The current gold standard for screening remains the dual-energy X-ray absorptiometry (DEXA) scan. It provides a quantitative measurement of bone mineral density (BMD) and assigns a T-score that helps stratify risk. DEXA is widely available, cost-effective, and invaluable for baseline assessment and longitudinal tracking. However, BMD alone does not tell the whole story. Bone strength is not just about density—it is also about quality, vascular supply, and structural integrity. This is where advanced imaging begins to fill critical gaps.

Ultrasound, particularly high-resolution musculoskeletal ultrasound, is emerging as a powerful adjunct in early osteoporosis detection. Unlike DEXA, ultrasound allows real-time evaluation of cortical bone surfaces, periosteal irregularities, and surrounding soft tissue. More importantly, Doppler ultrasound can assess microvascular flow, offering insight into bone perfusion—an underappreciated factor in bone health. Reduced vascularity may precede measurable density loss, providing an earlier warning signal. In a precision-medicine model, this kind of functional imaging helps us detect risk before it becomes structural failure.

Other modalities also contribute to a more comprehensive picture. Quantitative computed tomography (QCT) provides three-dimensional assessment of bone density and can distinguish between cortical and trabecular bone compartments. This is particularly useful in complex or high-risk patients where subtle changes may be missed on DEXA. Trabecular Bone Score (TBS), often derived from DEXA data, adds another layer by estimating bone microarchitecture. Meanwhile, MRI—though not routinely used for screening—can reveal bone marrow changes and early insufficiency fractures in symptomatic patients.

Emerging technologies are pushing the boundaries even further. High-frequency ultrasound systems and elastography are being explored for their ability to assess bone stiffness and mechanical properties. These tools align with a broader shift in medicine: moving from static imaging to dynamic, functional evaluation. The goal is not simply to measure bone—but to understand its behavior under stress, its vascular support, and its capacity to withstand injury

Early detection must also be individualized. Patients with hormonal imbalances, thyroid disorders, cancer treatment histories, or chronic inflammatory conditions may require earlier and more nuanced screening strategies. Waiting until age-based guidelines trigger a DEXA scan may miss years of preventable decline. Imaging should be integrated with clinical risk factors, laboratory data, and lifestyle assessment to create a full risk profile.

Ultimately, the future of osteoporosis care is proactive. The tools already exist—we simply need to apply them earlier and more intelligently. By combining DEXA with advanced ultrasound, Doppler analysis, and complementary imaging technologies, we can identify bone vulnerability at its earliest stages. In doing so, we shift the conversation from fracture management to fracture prevention—preserving not just bone density, but independence, mobility, and quality of life.

STRESS IN MALE BREAST CANCER

 Why Emotional Health Must Be Part of Survivorship Care

Co-Written by Dr. Barbara Bartlik and Dr. Robert L. Bard

Cancer care has traditionally focused on surgery, chemotherapy, radiation, medications, and imaging. Yet one of the most powerful influences on health outcomes often receives far less attention: stress. According to integrative psychiatrist Dr. Barbara Bartlik and diagnostic imaging specialist Dr. Robert L. Bard, chronic stress and anxiety are not merely emotional burdens—they can become biological burdens that affect healing, immune resilience, inflammation, sleep quality, and quality of life.

Their message is clear: no cancer treatment plan is complete unless it addresses the mind and body together.

Understanding the Stress Response

Stress is the body’s natural alarm system. In short bursts, it can be useful. It helps us react to danger, sharpen focus, and mobilize energy. But when stress becomes chronic—as it often does during diagnosis, treatment, financial strain, uncertainty, or fear of recurrence—the body can remain trapped in a constant state of physiological alert.

This prolonged stress response activates the adrenal glands, which release cortisol and adrenaline. These hormones are helpful during emergencies, but harmful when elevated for long periods.

Persistently high cortisol has been associated with:

• Suppressed immune surveillance
• Increased inflammation
• Sleep disruption
• Insulin resistance
• Weight gain or muscle loss
• Mood instability
• Fatigue and burnout
• Impaired tissue repair

For someone navigating cancer or survivorship, these effects can be especially significant.

Stress and the Immune System

The immune system plays a central role in monitoring abnormal cells, fighting infection, and assisting recovery after treatment. Chronic anxiety may weaken this system by altering white blood cell function, inflammatory signaling, and restorative sleep cycles.

Dr. Bartlik emphasizes that emotional trauma, unresolved fear, depression, and persistent hypervigilance can keep the nervous system in “fight-or-flight” mode. When the body never fully returns to calm, healing resources are diverted away from restoration.

This does not mean stress “causes cancer” in a simplistic sense. Cancer is complex and multifactorial. Genetics, environment, lifestyle, exposures, hormones, and age all matter. However, unmanaged stress can aggravate biological terrain, worsen symptoms, and diminish the body’s ability to recover optimally.

Cortisol, Inflammation, and Disease Burden

Inflammation is one of the most discussed pathways in modern medicine. While acute inflammation helps healing, chronic inflammation may contribute to pain, metabolic dysfunction, vascular strain, mood disorders, and fatigue.

Stress hormones can intensify inflammatory cascades. Survivors often describe feeling “wired but tired”—an exhausted state marked by anxiety, poor sleep, racing thoughts, and low resilience. This is where psychiatry, lifestyle medicine, and rehabilitation can become powerful allies.

Dr. Bartlik advocates a whole-person approach that may include:

• Nutritional support
• Sleep restoration
• Mindfulness and breathing practices
• Trauma-informed therapy
• Exercise prescriptions
• Nutraceutical support when appropriate
• Medication when clinically indicated
• Social connection and purpose-building

The Cancer Diagnosis Itself Is a Stress Event

A cancer diagnosis is not only a medical event—it is a psychological earthquake. Even patients with excellent prognoses may experience panic, grief, anger, isolation, or catastrophic thinking. During treatment, many face body-image changes, pain, financial pressure, career uncertainty, and family strain.

After treatment ends, many expect life to return to normal. Instead, survivorship often brings a new challenge: silent anxiety. Fear of recurrence, ongoing fatigue, hormonal shifts, cognitive fog, and loss of confidence can linger for years.

This is where post-treatment rehabilitation becomes essential.

Survivorship Is More Than “Cancer-Free”

Dr. Robert L. Bard has long advocated that survivorship should not be measured only by whether visible disease is gone. It should also be measured by how the patient functions physically, mentally, hormonally, socially, and emotionally.

He argues that many survivors are declared “finished” with treatment while still struggling with:

• Chronic fatigue
• Lymphedema
• Neuropathy
• Brain fog
• Anxiety and depression
• Loss of strength
• Sleep disorders
• Pain syndromes
• Hormonal imbalance
• Deconditioning
• Fear of movement

These are rehabilitation issues—and they deserve clinical attention.

How Rehabilitation Reduces Stress Biology

Cancer rehabilitation is one of the most underutilized tools for stress reduction. When survivors regain function, movement, strength, and confidence, the nervous system often shifts out of chronic threat mode.

Dr. Bard supports multidisciplinary survivorship rehab that may include:

• Physical therapy
• Strength training
• Balance and fall-prevention work
• Lymphedema therapy
• Massage and myofascial care
• Cognitive rehabilitation
• Nutritional counseling
• Integrative psychiatry
• Sleep medicine
• Mind-body coaching

Movement itself can be medicine. Exercise has been shown to support mood regulation, insulin sensitivity, sleep quality, circulation, and inflammatory balance. Even walking programs, resistance bands, yoga, tai chi, or supervised recovery exercise can create profound gains.

Imaging, Insight, and Personalized Recovery

As a diagnostic imaging specialist, Dr. Bard emphasizes that recovery should be personalized, not generic. Advanced imaging can help identify inflammation, vascular compromise, musculoskeletal strain, scar tissue behavior, or other treatable contributors to pain and dysfunction.

When patients understand why they hurt or where limitations exist, anxiety often decreases. Information reduces fear. Objective findings can guide smarter rehabilitation plans and provide measurable progress markers.

The Emotional Side of Healing

Dr. Bartlik notes that healing requires safety. Patients who feel heard, supported, and empowered often do better emotionally than those who feel dismissed or rushed. Compassionate medicine lowers stress. Human connection matters.

Support groups, counseling, spiritual care, journaling, creative arts, and relationship repair can all become part of survivorship medicine. There is no single path—but there should always be a path.

A New Standard of Care

Stress and anxiety should no longer be considered side issues in oncology. They are central variables affecting resilience, adherence, sleep, inflammation, mood, and recovery capacity. The future of cancer care is integrated care—where oncologists, imaging specialists, psychiatrists, rehab teams, nutrition experts, and exercise professionals work together.

As Drs. Bartlik and Bard would agree: surviving cancer is not the finish line. Restoring peace, strength, confidence, and quality of life is where the next chapter begins.

 

"WAS I FIRED BECAUSE OF CANCER?" (Draft only- not for distribution)

The Hidden Employment Crisis Potentially Facing Cancer Patients

 A Social Commentary By: Lennard M. Goetze, Ed.D / Barbara Bartlik, MD

Disclaimer: This commentary does not suggest that employers openly terminate workers because they have cancer. In most cases, employment actions are tied to broader issues such as prolonged absences, repeated medical leave, reduced availability, performance disruption, staffing pressures, or disputes over accommodations during treatment. However, as reports and legal complaints continue to surface, serious illness—particularly cancer requiring extensive time away from work—can place employees in a vulnerable position where their job security may be jeopardized. This social commentary examines that growing concern: the intersection of health hardship, workplace pressures, and the need for fairer protections for individuals managing life-threatening disease while trying to remain employed.

Cancer changes everything in a moment. It alters health, finances, family dynamics, and emotional stability. Yet for many patients, another crisis quietly emerges after diagnosis: the fear of losing their job. While public conversations often focus on treatment and survival, far less attention is given to employment vulnerability—the growing pattern of workers being sidelined, pressured out, or terminated after serious illness.

Advocates describe it as one of the most overlooked burdens of cancer care. Four-time cancer survivor and patient advocate SCOTT BAKER has seen it firsthand. Through years of supporting patients and families, he says many workers discover that the moment they need compassion most is when job security becomes uncertain.

“There are certain businesses where it’s just too much time off,” Baker explained. “They need you to be a ten out of ten every day, so they say, we can’t keep you.”  This is not simply an HR issue. It is a public health concern, an economic concern, and increasingly, a legislative concern.

 

The Unspoken Pattern of Employment Risk

Many workers assume that once diagnosed with cancer, legal systems automatically shield them from termination. The reality is more complicated. Some protections exist under disability and leave laws, but they are often narrow, time-limited, or dependent on company size, job tenure, and documentation requirements. That leaves countless employees exposed.

Baker recalled cases involving young nurses who had been employed for less than a year when they were diagnosed. Because they had not yet qualified for leave protections, they were let go. “They didn’t qualify for FMLA, so they just let them go,” he said.

Healthcare workers themselves are not immune. In fact, Baker emphasized that hospitals and medical institutions can reflect the same pressures seen in other industries—staffing shortages, productivity demands, and limited tolerance for extended absence. For patients, the message can feel brutal: get well quickly, or become replaceable.

Even After Treatment, the Battle Continues

One of the least understood realities of cancer recovery is that treatment completion does not equal full recovery. Many survivors return to work carrying fatigue, neuropathy, cognitive fog, anxiety, chronic pain, or emotional trauma. “They come back, and they’re not the same,” Baker noted. “It takes a long time to recover.”

This creates a dangerous gap. Employers may expect immediate peak performance, while survivors are still rebuilding physically and mentally. In fast-paced or high-output environments, workers may be quietly managed out, demoted, or judged against pre-illness standards. The result is a second trauma layered on top of the first.

 

The Self-Employed Face a Different Crisis

For entrepreneurs, freelancers, and small business owners, illness can be even more devastating. There may be no paid leave, no corporate benefits, and no substitute income stream. “They go from breadwinner to no bread,” Baker said bluntly.  This group often falls through policy cracks. They are workers without the protections many traditional employees assume exist.

 

What Can Be Done Legislatively?

Advocates increasingly argue that cancer survivorship must include employment security. Several reforms could make a meaningful difference:

1. Expand Medical Leave Eligibility: Current leave laws often exclude newer employees, part-time workers, or workers in smaller companies. Reform should shorten waiting periods and broaden eligibility for serious illness.

2. Modernize Temporary Disability Benefits: Baker recently advocated for reform of temporary disability insurance, noting that some benefit levels remain shockingly outdated. “$189 a week is not cutting it,” he said. For many families, that amount would not cover transportation to treatment, let alone rent or groceries.

3. Protect Return-to-Work Rights: Legislation could require reasonable phased returns, flexible scheduling, and medical accommodation for cancer survivors re-entering the workforce.

4. Strengthen Anti-Retaliation Enforcement: Some workers are not formally fired—they are squeezed out through reduced hours, negative reviews, or hostility after disclosure. Better enforcement mechanisms are urgently needed.

5. Incentivize Retention: Tax credits or subsidies for employers who retain and accommodate workers undergoing treatment could turn compassion into practical policy.

Work-Arounds for Workers Right Now

Until laws catch up, patients need strategies:

·   Disclose medical issues carefully and document all communications.

·   Request accommodations in writing.

·   Understand leave rights under federal and state law.

·   Consult employment attorneys or patient advocacy groups early.

·   Build relationships with supervisors who may advocate internally.

Baker credits a supportive supervisor with helping save his own position during prolonged treatment. Without that ally, the outcome may have been very different.  That should not depend on luck.

A Larger Moral Question

How a society treats workers during illness reveals its values. Cancer patients are not disposable assets. They are teachers, nurses, tradespeople, executives, parents, veterans, and community members fighting for their lives. To punish illness with unemployment is not efficiency—it is failure.

 

Conclusion

The hidden employment crisis facing cancer patients deserves national attention. Behind many survival stories lies another story of lost income, lost dignity, and preventable hardship. The goal of modern medicine is not merely to keep people alive—it is to preserve their ability to live.

Scott Baker’s warning is clear: the risk is real, widespread, and often invisible. The next frontier of survivorship is not only better treatment. It is better protection. No one battling cancer should also have to battle for the right to keep their job.

 

PART 2: CLINICAL PERSPECTIVE

WORK IS MEDICINE: WHY A CANCER DIAGNOSIS SHOULD NOT END A PERSON’S CAREER

Written by Dr. Robert L. Bard

I have spent my professional life studying disease through imaging, diagnostics, and the realities of patient care. Over decades of working with cancer patients, I have learned one truth that too many employers fail to understand: a cancer diagnosis does not automatically mean disability, incapacity, or the end of productivity.

That is why I stand in full support of the concerns raised by Scott Baker in his important discussion about workers being fired because of cancer. This issue is real, it is harmful, and in many cases, it is based on fear rather than fact. Too often, people are judged by a diagnosis instead of their actual condition, their strength, or their ability to contribute. As physicians, employers, and as a society, we must do better.

The Diagnosis Is Not the Disability

One of the greatest misconceptions in the workplace is the belief that once a person hears the word “cancer,” they are no longer able to function. This is medically inaccurate. Many cancers today are treatable, manageable, slow-growing, or responsive to therapy. Some remain stable for years or decades.

I have personally followed patients with low-grade prostate cancer who continue to live normal, active, productive lives. With modern imaging, surveillance, and appropriate care, we can often confirm that their condition has not progressed and does not impair their daily function.

I have also known patients with metastatic disease who still climb stairs, go to work, care for families, and remain deeply engaged in life. Their diagnosis did not define their usefulness. Their resilience did.

Work Can Be Healing

Employment is not only about income. Work gives structure, purpose, identity, dignity, and hope. For many patients, returning to work or continuing to work becomes part of recovery. It restores normalcy during a frightening time. It reminds them they are still needed.

I recall experiencing severe postoperative pain years ago after a dental procedure. The discomfort was so intense that I went back to work simply to focus my mind on something productive rather than on suffering. That experience taught me that meaningful activity can help redirect pain, anxiety, and despair. Cancer patients deserve that same opportunity.

The Role of Medical Verification

Today we have advanced tools that can help objectively assess a patient’s status. Through ultrasound imaging, Doppler flow studies, elastography, and other noninvasive technologies, we can monitor tumor behavior, treatment response, and physical function.

This means decisions about employment should not be based on assumptions or stigma. They should be based on facts. If a patient is medically capable of working, physicians should feel empowered to document that reality. Employers should welcome that guidance rather than fear it.

A Special Concern: Healthcare Workers

I was especially troubled to hear reports of nurses and healthcare workers losing jobs soon after a diagnosis. That is not only unjust—it is counterproductive.

When a nurse with cancer continues to serve with strength and professionalism, it sends a powerful message to every patient in that hospital: survival is possible, life continues, and illness does not erase value. Those workers become living symbols of courage. To remove them because “it doesn’t look good” is a failure of compassion and leadership.

Final Word

A cancer diagnosis should trigger support, not suspicion. It should lead to accommodation where needed, not automatic termination. We need stronger workplace protections, physician-backed return-to-work pathways, and a national understanding that many people with cancer can continue to live and work successfully.

Cancer is a health challenge. It should never become an employment sentence.

 

 

NEWS REFERENCES:

1. United Airlines Employee Claims He Was Fired Mid-Chemo Session: A United Airlines worker with stage 4 lymphoma alleged he was fired over the phone during chemotherapy for “taking too much time off work.” Read People Magazine Report

---

2. Independent Report on Same United Airlines Lawsuit: Detailed coverage of the federal complaint, including allegations he continued working while undergoing treatment. Read The Independent Report

---

3. Black Enterprise Coverage: Fired After Using PTO for Chemotherapy: Follow-up reporting focused on the use of accrued leave for cancer treatment and alleged termination. Read Black Enterprise Report

---

4. Nurse Alleges Firing While Fighting Breast Cancer: Public reporting described a nurse claiming termination after requesting leave connected to surgery and treatment. (Referenced in prior public reports.) Search Related Public Coverage

---

5. Workers Losing Jobs Before FMLA Eligibility: The United complaint alleges termination one week before the employee qualified for federal protected leave. Read FMLA Allegation Details

---

6. National Pattern: Cancer Patients Reporting Employment Retaliation- This case has drawn public attention because it reflects a broader pattern of workers claiming punishment after serious diagnoses. Read National Discussion Coverage

---

7. Lawsuit Includes ADA Disability Discrimination Claims: The complaint reportedly includes violations under the Equal Employment Opportunity Commission framework and disability law standards. Read Legal Allegations

---

8. “No One Should Have to Choose Between Health and Livelihood”: The employee’s attorney framed the case as forcing workers to choose between treatment and employment. Read Attorney Statement